FDA Approves BRCA Breast Cancer Drug — With $13K-A-Month Pricetag
BRCA2: A mutation on a gene associated with breast and ovarian cancer also raises the risk of prostate cancer. Image by Protein Design Bank
(JTA) — Regulators in the United States have approved a drug for women with advanced breast cancer caused by BRCA gene mutations, which disproportionately affects Ashkenazi Jewish women.
The Food and Drug Administration approved AstraZeneca PLC’s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy, the FDA said in a statement. The approval was announced on Friday.
The drug has been on the market since 2014 for ovarian cancer, and recently has been approved to treat breast cancer. It is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a BRCA gene mutation.
“This class of drugs has been used to treat advanced, BRCA-mutated ovarian cancer and has now shown efficacy in treating certain types of BRCA-mutated breast cancer,” said Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence.
Approximately 20 percent to 25 percent of patients with hereditary breast cancers and up to 10 percent of patients with any type of breast cancer have a BRCA mutation.
The fast-tracked approval of Lynparza was based on a trial of 302 women with metastatic breast cancer and a BRCA gene mutation. The drug delayed the spread of the cancer for seven months as opposed to four months for women taking chemotherapy only, according to the FDA.
Lynparza will cost $13,886 per month without insurance, the Associated Press reported, citing AstraZeneca.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.
In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.
At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.
Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we still need 300 people to step up and make a gift to sustain our trustworthy, independent journalism.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
Only 300 more gifts needed by April 30
